NOVARTIS logo.jpg
Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study
June 03, 2021 12:04 ET | Novartis Pharma AG
Men who received 177Lu-PSMA-617 plus best standard of care had a 38% reduction in risk of death (median OS benefit of 4 months) and a 60% reduction in the risk of radiographic disease progression or...
NOVARTIS logo.jpg
Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma
June 02, 2021 09:05 ET | Novartis Pharma AG
Primary analysis of ELARA trial demonstrated a 66% complete response rate and 86% overall response rate with one-time Kymriah infusion1Robust response observed in heavily pretreated patients in...
NOVARTIS logo.jpg
Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
June 02, 2021 09:00 ET | Novartis Pharma AG
MONALEESA-3 median overall survival (OS) results of 53.7 months underscore that Kisqali offers more life to postmenopausal women with HR+/HER2- metastatic breast cancer (MBC) in addition to the OS...
NOVARTIS logo.jpg
Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer
May 19, 2021 17:00 ET | Novartis Pharma AG
Overall survival and radiographic PFS from phase III study of investigational radioligand therapy 177Lu-PSMA-617 VISION trial of patients with metastatic castration-resistant prostate cancer to be...
NOVARTIS logo.jpg
Wichtige Wachstumstreiber und Neueinführungen von Novartis setzen ihre Dynamik im ersten Quartal fort und erhalten das Vertrauen in das Wachstum; Konzernprognose für 2021 bestätigt
April 27, 2021 01:00 ET | Novartis Pharma AG
Der Nettoumsatz sank im ersten Quartal um –2% (kWk¹, +1% USD) infolge der COVID-19-bedingten Vorratskäufe im Vorjahr (rund USD 0,4 Milliarden) Die Geschäftseinheit Pharmaceuticals blieb auf...
NOVARTIS logo.jpg
Novartis: moteurs clés de la croissance et lancements poursuivent leur essor au 1er trimestre, maintenant la confiance dans la croissance. Confirmation des prévisions pour le Groupe pour 2021
April 27, 2021 01:00 ET | Novartis Pharma AG
Chiffre d’affaires net du T1 en recul de -2% (tcc¹, +1% USD), impacté par les achats anticipés au T1 2020 en lien avec le Covid-19 (env. USD 0,4 milliard) Pharmaceuticals: le chiffre d’affaires net de...
NOVARTIS logo.jpg
Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed.
April 27, 2021 01:00 ET | Novartis Pharma AG
Q1 net sales declined -2% (cc¹, +1% USD), due to prior year COVID-19 related forward purchasing (approximately USD 0.4 billion) Pharmaceuticals BU in line with prior year (0% cc, +4% USD) with...
NOVARTIS logo.jpg
Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)
March 30, 2021 01:15 ET | Novartis Pharma AG
Expands Novartis Oncology radioligand pipeline with exclusive worldwide rights to develop and commercialize therapeutic applications for a library of FAP assets including FAPI-46 and FAPI-74Broad...
NOVARTIS logo.jpg
Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer
March 23, 2021 02:15 ET | Novartis Pharma AG
Phase III VISION study with 177Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive...
NOVARTIS logo.jpg
New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment
March 15, 2021 06:00 ET | Novartis Pharma AG
Children with SMA treated presymptomatically achieved age-appropriate motor milestones including sitting, standing and walking; required no ventilatory or feeding tube support; and had no serious,...